October 30, 2009 15:16 ET

Benjamin L. England of to Give Presentation at 2009 China Seafood Expo

WASHINGTON, DC--(Marketwire - October 30, 2009) - The 14th annual China Fisheries & Seafood Expo will be held in Quindao the first week of November. Last year's expo saw 735 exhibiting companies and an estimated 15,000 qualified buyers. The seafood industry in China is booming. Meanwhile, each month, many shipments of seafood from China are refused by the U.S. Food and Drug Administration for import into the U.S.

Many of the shipments refused and returned to China were simply not labeled properly. FDA did not even take a sample of the product to see its quality; the fact that the label did not conform to FDA labeling rules was enough for FDA to refuse the shipment.

Others were refused because they contained "new animal drugs" -- that is, a drug was administered to keep the fish healthy, but that drug is not approved in the U.S. for feeding to animals, particularly animals that will be consumed by humans. Recent "new animal drugs" FDA found in farm-raised seafood from China are fluroquinolones, malachite green, nitrofurans, and gentian violet.

Still other shipments were refused because they appeared to be dirty, decomposed, or contaminated with bacteria or deleterious substances. Sometimes, FDA has made these judgments and refusals without a sample analysis.

Since 2001, FDA has issued country-wide "Import Alerts" prohibiting the importation of many seafood products from China, including more recently aquaculture catfish, basa, shimp, dace, and eel. Such shipments are subject to FDA Automatic Detention (or Detention Without Physical Examination), which often results in FDA refusals of admission -- and exportation back to China.

With so many forms of rejection by FDA, companies in China may find themselves at a loss when it comes to successfully selling their seafood in the U.S. For causes like this, Benjamin L. England, an attorney with a 17-year career with FDA, has founded, which specializes in showing firms "the way through" to successfully import their products into the U.S.

Mr. England is an expert in helping firms develop, gather, and present the evidence necessary to obtain access to the U.S. market and reduce the chance of FDA import refusals. He has gathered a team of former FDA and USDA officials, both regulatory consultants and legal professionals, who routinely achieve success for Chinese seafood exporters to the United States.

Mr. England will be leading a seminar in China on Wednesday, November 4, entitled: "The Way Through: 21st Century Compliance Strategies for Exporting Seafood Products to the United States." Attendees will gain a comprehensive overview of the U.S. laws and regulations governing the importation of seafood products regulated by FDA. They will be updated on recent developments within the laws affecting importing, and learn how companies can become exempt from the import alerts issued by FDA and get their products into the U.S. marketplace.

Mr. England will discuss the various import alerts affecting seafood products and processors, FDA's changing perspectives on seafood HACCP, and important strategies to satisfying FDA that a firm's processes and products comply with U.S. requirements. Mr. England has a cutting-edge perspective from which he gauges both the future direction of FDA's renewed commitment to enforcement and the new Congressional legislation affecting imported products including seafood products. He is willing to share it at this seminar, and he is available for counsel year-round at his office at

Contact Information

  • Contact:
    Benjamin England
    Rick Quinn